Search Results

You are looking at 31 - 40 of 96 items for :

  • Refine by Access: Content accessible to me x
Clear All

) analysis, he found that African Americans report unique motivations for using MDMA. However, he concedes that these results, obtained from a small, low socioeconomic (SES) sample, may not be representative. In his recommendations for further research, Rigg

Open access

psychedelic substances for the treatment of psychological disorders. This has included the administration of a range of substances, including LSD, psilocybin, ayahuasca, methylenedioxymethamphetamine (MDMA), and ibogaine, in conjunction with psychotherapy for

Open access

(broadly inclusive of psilocybin, lysergic-acid diethylamide [LSD], ketamine, and 3,4-Methylenedioxymethamphetamine [MDMA]) with psychotherapy could enhance intrinsic aspects related to recovery capital such as motivation, connectedness, self-efficacy and

Open access
Journal of Psychedelic Studies
Authors:
John M. Clifton
,
Annabelle M. Belcher
,
Aaron D. Greenblatt
,
Christopher M. Welsh
,
Thomas O. Cole
, and
Alan K. Davis

, methamphetamines, heroin, prescription opioids, benzodiazepines, cocaine/crack, LSD, mescaline, mushrooms, DMT, salvia PCP, and MDMA (ecstasy). Perceived risk Participants were asked whether they had ever heard of

Open access

Introduction Psychedelic drugs like lysergic acid diethylamide (LSD-25), 3,4-methylenedioxymethamphetamine (MDMA), and psilocybin are being investigated again, showing therapeutic potential for certain psychological disorders

Open access
Journal of Behavioral Addictions
Authors:
Pedro Romero
,
Andrea Czakó
,
Wim van den Brink
, and
Zsolt Demetrovics

research indicates the potential of psychedelic-assisted therapy (PAT) to treat treatment-resistant mental disorders, including various substance use disorders ( Andersen, Carhart-Harris, Nutt, & Erritzoe, 2021 ). While atypical psychedelics (e.g., MDMA

Open access

treatment assignment can significantly influence both placebo and nocebo effects in psychedelic therapy. In a similar vein, Flameling, Aday, and Van Elk (2023) point out the potential for both placebo and nocebo effects in MDMA trials. It is described that

Open access
Journal of Psychedelic Studies
Authors:
Cody Sykes Gilbert
,
Mitch Earleywine
,
Maha N. Mian
, and
Brianna R. Altman

., 2007 ). Researchers once praised MDMA, which increases activity in both systems, as a potential antidepressant ( Riedlinger & Riedlinger, 1994 ). MDMA-assisted treatment for other disorders appear to help depressive symptoms , though those in the

Open access

, Wiegand, Taitano, & Delgado, 2006 ), end-of-life anxiety ( Griffiths et al., 2016 ), and substance use disorders ( Johnson, Garcia-Romeu, Cosimano, & Griffiths, 2014 ; Sessa et al., 2021 ). Most notably, the FDA designated MDMA-assisted psychotherapy a

Open access

classes: classical psychedelics (e.g. Psilocybin, LSD, DMT), entactogens (e.g. MDMA), dissociative anaesthetics (e.g. Ketamine), and atypical hallucinogens (e.g. Ibogaine). Each of these different classes are characterised by unique pharmacological

Open access